‘Free’ vaccines, single-dose nudge pushes India-made HPV vaccine to back of the line

A pivotal study spearheaded by the Indian Council of Medical Research (ICMR) is underway to evaluate the efficacy of Cervavac, India’s domestically produced HPV vaccine. The research aims to determine whether a single dose of Cervavac can generate sufficient protective antibodies and maintain a stable immune response, particularly in comparison to the established Gardasil vaccine. The findings of this study could influence future recommendations for Cervavac’s use, potentially enhancing its role in India's vaccination strategy against human papillomavirus (HPV), which is linked to cervical cancer. Despite the promising aspects of Cervavac, the vaccine currently faces challenges due to competing options, including free vaccines and public perceptions favoring established brands like Gardasil. As the study progresses, the outcomes will be crucial for determining the vaccine's place in public health initiatives, particularly in a country with a significant burden of cervical cancer, where timely vaccination is vital for prevention. Stakeholders in the healthcare sector are closely monitoring the results, as they could reshape the landscape of cervical cancer prevention in India.